IXICO boss on 'tech bio' deal that creates solution for clinical trials - ICYMI

Core Viewpoint - IXICO PLC has entered a strategic collaboration with Medidata, aiming to enhance clinical trial solutions and drive growth through expanded access to larger trials and recurring revenue streams [2][4][6] Group 1: Partnership Details - The collaboration combines IXICO's neuroimaging analytics with Medidata's global clinical trial platform, creating a seamless solution for biopharma clinical trials [3][4] - Medidata is a significant player in the clinical trial space, serving 18 of the top 25 pharmaceutical companies and managing around 38,000 trials across 140 geographies [4] Group 2: Growth Strategy - The partnership is expected to facilitate IXICO's entry into the "tech bio" space, allowing the company to leverage its proprietary IXI platform for more complex trials [6] - IXICO aims to build recurring revenue streams through long-term collaborations rather than one-off projects, which should accelerate growth and create new revenue opportunities [7] Group 3: Recent Developments - IXICO recently extended a large global Phase 2 trial worth £1.5 million and welcomed a new Chief Commercial Officer, enhancing its leadership and commercial strategy [5][6]